Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency

NCT06205758 is registered in ClinicalTrials.gov with Yi Han as lead sponsor.

NCT NCT06205758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06205758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency
Lead sponsor
Yi Han
Phase
Observational
Overall status
Unknown status
Start date
November 16, 2023
Completion date
June 1, 2025
Enrollment
1,600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, heart failure, levosimendan, milrinone, safety